Study Details

Back to Search Results

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03282318

Astellas Study ID

The unique identification code given by the study sponsor.

6294-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2016-004138-12

Follow Trial

Condition

Bladder Pain Syndrome

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2017 - Mar 2019

Masking

Double (Participant, Investigator)

Enrollment number

119

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects with Bladder Pain Syndrome/Interstitial Cystitis? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site NL31007

Sneek, Netherlands

Site PL48010

Warszawa, Poland

Site ES34006

Barcelona, Spain

Site GB44006

Plymouth, United Kingdom

Site RU70006

St. Petersburg, Russian Federation

Site DE49007

Duisburg, Germany

Site ES34005

La Cuesta, Spain

Site RU70002

St. Petersburg, Russian Federation

Site ES34007

Valencia, Spain

Site GB44002

Manchester, United Kingdom

Site LV37103

Daugavpils, Latvia

Site DE49002

Nuertingen, Germany

Site CZ42001

Kromeriz, Czech Republic

Site HU36006

Gyor, Hungary

Site BE32001

Leuven, Belgium

Site LV37102

Riga, Latvia

Site PL48007

Wroclaw, Poland

Site PL48009

Lodz, Poland

Site RU70001

St. Petersburg, Russian Federation

Site NL31005

Nijmegen, Netherlands

Site GB44001

Glasgow, United Kingdom

Site HU36001

Csongrad, Hungary

Site LV37105

Riga, Latvia

Site GB44004

Wrexham, United Kingdom

Site DE49001

Holzminden, Germany

Site PL48001

Lublin, Poland

Site CZ42003

Praha 4, Czech Republic

Site NL31001

Rotterdam, Netherlands

Site ES34002

Malaga, Spain

Site DE49011

Berlin, Germany

Site PL48004

Chorzow, Poland

Site CZ42002

Plzen, Czech Republic

Site DE49005

Markkleeberg, Germany

Site LV37101

Riga, Latvia

Site HU36002

Budapest, Hungary

Site PL48002

Szczecin, Poland

Site PL48006

Katowice, Poland

Site PL48003

Bialystok, Poland

Site ES34001

Barcelona, Spain

Site ES34008

Madrid, Spain

Site BE32002

Edegem, Czech Republic

Site RU70003

St. Petersburg, Russian Federation

Site NL31002

Doetinchem, Netherlands

Site DE49010

Monchengladbach, Germany

Site RU70008

St. Petersburg, Russian Federation

Site DE49003

Duisburg, Germany

Site RU70005

Moscow, Russian Federation

Site ES34003

Madrid, Spain

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo